Baltimore, Maryland/ February 14, 2019—Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a new research report on fast-growing agriculture biotechnology provider Kiwa Bio-Tech Products Group Corp. (OTC – KWBT), highlighting recent events and potential future share price valuations. To view this report, along with disclosures and disclaimers, or to download them in their entirety, please visit http://www.goldmanresearch.com.
Kiwa Bio-Tech Products Group Corp. develops, manufactures, markets and distributes innovative and environmentally safe bio-technological products for agriculture. Kiwa’s focus is to positively impact the environment by reducing the amount of chemicals that are being used by agricultural growers in China. Kiwa products are covered by patent protection and are designed to enhance the quality of human life by increasing the value and productivity of agricultural crops.
In the Goldman Small Cap Research Opportunity Research report, analyst Rob Goldman offers key insights into Kiwa’s fast-growing business and valuation.
Goldman noted, “There are four key factors in play with Kiwa which we believe will drive interest and valuation in these shares, going forward:”
Kiwa Bio-Tech is a pure play on the agbiotech industry in China
This opportunity represents a multi-billion-dollar global market. The Company’s bio-fertilizers enhance the quality and productivity of crops while simultaneously reducing the negative environmental impact of chemicals currently used.
Broad, mandated replacement of chemicals with bio-fertilizers directly benefits Kiwa
Recent China government action plans to spur “green” agriculture development growth includes the replacement of chemical bio-fertilizers with bio-fertilizers on vegetables, fruits and teas planting. Kiwa is the beneficiary of new initiatives. These events leave Kiwa well-positioned to win new, low-hanging business from centers that represent billions in annual fertilizer sales.
Kiwa is recording enviable top-line growth; could up-list shares
“Kiwa is in the early stages of a major revenue and EPS boom, led by new and existing products and markets, beginning in 2019, which is why management is contemplating a share up-listing to a senior exchange.” noted Goldman. Our model assumes 2018 and 2019 sales of $31.1M and $39.2M, respectively, with forecasted 2020 sales of $51.1M. We also project EPS will leap from $0.04 in 2018 to $0.18 in 2019 and $0.26 in 2020.”
A relative unknown, Kiwa’s financial performance will drive interest and valuation
“Against its industry backdrop, unique positioning, and financial performance, we believe Kiwa’s shares are undervalued. Our 12-month target price is based on its 44.4% expected EPS growth rate (’19 – ’20), which reflects a substantial increase in net profit margin, and yet low P/E and P/S ratios,” remarked Goldman. “Furthermore, as a relative unknown to many small cap investors despite its recent operating performance, we expect even an incremental increase in volume will have a positive impact on the Kiwa share price, given its low shares outstanding.”
About Goldman Small Cap Research:
Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published sponsored company research report on Kiwa Bio-Tech Products Group Corp. which carries a rating and a price target. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Kiwa Bio-Tech Products Group Corp. (“the Company”) authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was compensated $3500 by the Company for research and distribution services.
Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
About Kiwa Bio-Tech Products Group Corp.
Leader in Eco-friendly Agricultural Industry Chain
Kiwa Bio-Tech Products Group Corp. (KWBT) is a publicly traded company with corporate headquarters in the Yangling, Shaanxi, China. The company develops, manufacture, markets and distributes innovative and environmentally safe bio-technological products for agriculture. Kiwa’s focus is to positively impact the environment by reducing the amount of chemical fertilizers that are being used by agricultural growers in China.
Kiwa Bio-Tech Products Group Corp. products are covered by patent protection and are designed to enhance the quality of human life by increasing the value and productivity of agricultural crops.
For more information on Kiwa Bio-Tech Products Group Corp. or its bio-fertilizer products and smart soil remediation technology, please refer to the Company’s website at www.kiwabiotech.com or the Company filings with the United States Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the U.S. Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company’s actual results may differ materially from those anticipated in the forward-looking statements depending on a number of risk factors including, but not limited to, the following: general economic, business and environment conditions, development, shipment, market acceptance, additional competition from existing and new competitors, changes in technology, the execution of its ten-year growth plan, the foreign exchange risk amid the unexpected announcements by the PRC government and various other factors beyond the Company’s control. Kiwa Bio-Tech Products Group Corp. specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.
Contact:
Kiwa Bio-Tech Products Group Corporation
ir@kiwabiotech.com
原文链接:
https://finance.yahoo.com/news/goldman-small-cap-research-issues-135000712.html
